drugset
drugset / Trial / NCT03119519

Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer.

NCT03119519 ↗

Phase 2 Unknown 148 enrolled Southern Medical University, China
RandomizedParallel-groupOpen-labelTreatment

Summary

Aggressive therapy may improve survival in synchronous oligometastatic NSCLC and the goal of this clinical trial is to assess the efficacy and safety of local definitive radiotherapy in this subset of patients.

Timeline

Start
2017-12-11
Primary completion
2020-09
Completion
2021-09

Drugs

EvaluationDrugModalityDoseRoute
Background Erlotinib Small molecule — —
Background Gefitinib Small molecule — —

Indications

non-small cell lung carcinoma